Interesting news I wanted to share about one of several new anti-myeloma therapy agents, perifosine. Currently in Phase 3 trials in combination with Velcade, perifosine apparently has anti-cancer properties which go far beyond multiple myeloma:
Aeterna Zentaris Receives Positive Scientific Advice from the European Medicines Agency for its Phase 3 Trial with Perifosine in Colorectal Cancer
The multicenter X-PECT (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) Phase 3 study involving approximately 430 patients, is a double-blind, placebo-controlled study comparing the combination of perifosine and capecitabine (Xeloda(R)) with single-agent capecitabine (Xeloda(R)). Patients in this study have been intensively pre-treated and have failed all available treatment options except capecitabine (Xeloda(R)). Overall survival will be analyzed as the primary efficacy endpoint, with secondary endpoints including overall response rate (complete + partial responses), progression-free survival and safety.
Last April, Aeterna Zentaris had also received positive Scientific Advice from the EMA for the ongoing Phase 3 trial in multiple myeloma with perifosine, being conducted by Keryx in the United States. The trial is a double-blind, placebo-controlled study of perifosine combined with bortezomib (Velcade(R)) in bortezomib pre-treated patients. Progression-free survival is the primary efficacy endpoint in this trial, which will include follow-up for overall survival.
Read the entire article, including additional multiple myeloma related info by going to http://finance.yahoo.com/news/Aeterna-Zentaris-Receives-prnews-415521970.html?x=0&.v=1
Feel good and keep smiling! Pat